- Newsletter
- May 2024
- 14 Pages
United States
- Report
- March 2021
- 48 Pages
Global
€1267EUR$1,318USD£1,087GBP
- Drug Pipelines
- March 2019
- 111 Pages
Global
€9615EUR$10,000USD£8,249GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,125USD£897GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,125USD£897GBP
- Report
- May 2021
- 88 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- February 2024
- 77 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- April 2023
- 119 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- August 2022
- 871 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Drug Pipelines
- February 2020
- 52 Pages
Global
From €3365EUR$3,500USD£2,887GBP
- Report
- July 2023
- 199 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- July 2023
- 98 Pages
China
From €1731EUR$1,800USD£1,485GBP
- Report
- February 2019
- 201 Pages
Global
From €5163EUR$5,370USD£4,430GBP
- Report
- August 2020
- 113 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- February 2024
- 180 Pages
Global
From €5288EUR$5,499USD£4,536GBP
Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs.
Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated.
Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more